Results 1 to 10 of about 3,395 (155)
A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice [PDF]
Drugs - Real World Outcomes, 2019 Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-density lipoprotein
Tim Reynolds +8 more
doaj +6 more sources
Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017 BackgroundThe proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Peter P. Toth +13 more
doaj +3 more sources
Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis [PDF]
Reviews in Cardiovascular Medicine, 2021 Evaluation of the effects of alirocumab on cardiovascular (CV) events, CV mortality and all-cause mortality. Data search was carried out using the Cochrane Library, PubMed, Web of Science and Embase. The search time is up to November 18, 2020.
Wanting Wang +2 more
doaj +1 more source
Archives of Medical Science, 2021 Introduction The phase IIIb open-label ODYSSEY APPRISE study prospectively assessed the safety and efficacy of alirocumab (a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor) in a real-life setting in high cardiovascular risk patients with
Maciej Banach +8 more
doaj +1 more source
Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study [PDF]
The Korean Journal of Internal Medicine, 2019 Background/Aims Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population.
Chang-Wook Nam +6 more
doaj +1 more source
Kidney Medicine, 2022 Rationale & Objective: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab is used in the general population to treat dyslipidemia, but little is known about the effects of alirocumab on lipid levels, biomarkers, the ...
Cara East +5 more
doaj +1 more source
Effect of alirocumab on cataracts in patients with acute coronary syndromes
BMC Ophthalmology, 2023 Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone.
Gaspard Suc +10 more
doaj +1 more source
Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease
Open Heart, 2021 Background Atherosclerotic cardiovascular disease is the leading cause of death and disability in the Western world.Objective To characterise adults with confirmed coronary heart disease (CHD) and primary heterozygous familial or non-familial ...
Peter Bramlage +7 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 BackgroundLow-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and ...
Isabella Sudano +14 more
doaj +1 more source
Cancer Medicine, 2023 Objective Assess the risk of new and worsening cancer events among participants who received the lipid‐lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor. Design Pooled post hoc analysis. Setting Six phase 3 or phase 4
Kusha A. Mohammadi +8 more
doaj +1 more source